Analysts’ Top Healthcare Picks: AzurRx BioPharma Inc (AZRX), Albireo Pharma Inc (ALBO)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AzurRx BioPharma Inc (AZRXResearch Report) and Albireo Pharma Inc (ALBOResearch Report) with bullish sentiments.

AzurRx BioPharma Inc (AZRX)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on AzurRx BioPharma Inc today and set a price target of $7. The company’s shares closed yesterday at $2.14.

Selvaraju wrote:

“Our price target is derived from a market value of the firm at $189M, which includes a discounted cash flow-based asset value of $190M for MS1819, using a 15% discount rate and 2% terminal growth rate, excluding debt, with 50% probability of success.”

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -4.1% and a 27.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on AzurRx BioPharma Inc is a Strong Buy with an average price target of $6.67, implying a 211.7% upside from current levels. In a report issued on May 21, Maxim Group also maintained a Buy rating on the stock with a $5 price target.

See today’s analyst top recommended stocks >>

Albireo Pharma Inc (ALBO)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Albireo Pharma Inc today and set a price target of $62. The company’s shares closed yesterday at $33.75.

Arce commented:

“We expect ESPGHAN presentations to outline rationale of odevixibat in several liver diseases. Yesterday, Albireo announced its plan to participate as a presenter at the 52nd Nutrition (ESPGHAN) Annual Meeting, held Glasgow, Scotland. Specifically, we expect several presentations to include clinical data and investigator findings based on studies of Albireo’s lead candidate ileal bile acid transporter (IBAT) inhibitor, odevixibat (previously known as A4250), in progressive familial intrahepatic cholestasis (PFIC), biliary atresia (BA), and Alagille syndrome.”

According to TipRanks.com, Arce is a 4-star analyst with an average return of 7.9% and a 38.4% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.

Currently, the analyst consensus on Albireo Pharma Inc is a Strong Buy with an average price target of $60.33, implying a 78.8% upside from current levels. In a report issued on May 9, Cowen & Co. also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.